Candriam S.C.A. Sells 38,835 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Candriam S.C.A. lessened its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 674,257 shares of the biopharmaceutical company's stock after selling 38,835 shares during the quarter. Candriam S.C.A. owned approximately 0.73% of Ultragenyx Pharmaceutical worth $28,366,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in RARE. Alkeon Capital Management LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 34.3% during the third quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company's stock worth $167,301,000 after acquiring an additional 769,884 shares in the last quarter. Baker BROS. Advisors LP increased its position in Ultragenyx Pharmaceutical by 7.5% in the 3rd quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company's stock worth $87,553,000 after purchasing an additional 109,567 shares during the last quarter. Geode Capital Management LLC increased its position in Ultragenyx Pharmaceutical by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company's stock worth $87,296,000 after purchasing an additional 65,623 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of Ultragenyx Pharmaceutical by 123.4% during the 3rd quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company's stock worth $54,872,000 after purchasing an additional 545,600 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its holdings in shares of Ultragenyx Pharmaceutical by 35.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 653,660 shares of the biopharmaceutical company's stock valued at $36,311,000 after buying an additional 172,711 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Remove Ads

Insider Transactions at Ultragenyx Pharmaceutical

In other news, CEO Emil D. Kakkis sold 11,727 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $42.23, for a total transaction of $495,231.21. Following the sale, the chief executive officer now owns 2,183,985 shares of the company's stock, valued at approximately $92,229,686.55. This trade represents a 0.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John Richard Pinion sold 14,439 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $607,881.90. Following the sale, the insider now owns 107,766 shares in the company, valued at approximately $4,536,948.60. This represents a 11.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 144,643 shares of company stock worth $6,165,149. 5.80% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Stock Down 2.9 %

NASDAQ RARE traded down $1.12 during trading on Monday, hitting $37.50. The company's stock had a trading volume of 914,530 shares, compared to its average volume of 784,180. Ultragenyx Pharmaceutical Inc. has a 52 week low of $31.66 and a 52 week high of $60.37. The firm has a market cap of $3.47 billion, a P/E ratio of -5.91 and a beta of 0.67. The firm has a 50 day moving average price of $42.57 and a 200 day moving average price of $48.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analyst Weigh In

RARE has been the topic of a number of research reports. Piper Sandler increased their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an "overweight" rating in a report on Monday, January 13th. Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research note on Friday, December 20th. Wedbush reaffirmed a "neutral" rating and issued a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Canaccord Genuity Group increased their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.